Q1 Earnings Estimate for ABEO Issued By Zacks Small Cap

Abeona Therapeutics Inc (NASDAQ:ABEO) – Zacks Small Cap issued their Q1 2025 earnings estimates for Abeona Therapeutics in a research note issued on Monday, March 24th. Zacks Small Cap analyst D. Bautz expects that the biopharmaceutical company will earn ($0.34) per share for the quarter. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics’ Q2 2025 earnings at ($0.33) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.19.

Other equities analysts have also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a report on Monday. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. Finally, Oppenheimer assumed coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 target price for the company. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.50.

Abeona Therapeutics Stock Up 1.0 %

Shares of ABEO opened at $5.04 on Wednesday. The firm has a 50 day simple moving average of $5.42 and a two-hundred day simple moving average of $5.81. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. Abeona Therapeutics has a one year low of $3.05 and a one year high of $8.45. The company has a market cap of $219.09 million, a P/E ratio of -1.87 and a beta of 1.79.

Institutional Investors Weigh In On Abeona Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Twinbeech Capital LP acquired a new position in shares of Abeona Therapeutics during the fourth quarter worth $58,000. Squarepoint Ops LLC bought a new position in Abeona Therapeutics during the 4th quarter worth $67,000. Jane Street Group LLC acquired a new position in Abeona Therapeutics during the 3rd quarter worth about $84,000. Oxford Asset Management LLP bought a new stake in shares of Abeona Therapeutics in the 4th quarter valued at about $118,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Abeona Therapeutics in the third quarter valued at about $151,000. 80.56% of the stock is owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.